Barclays Maintains Equal-Weight on Alkami Technology, Lowers Price Target to $15
Barclays analyst Saket Kalia maintains Alkami Technology (NASDAQ:ALKT) with a Equal-Weight and lowers the price target from $21 to $15.
Stocks · News reference
This Yum Brands Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Thursday
Wall Street analysts downgraded Rollins, Yum Brands, Alkami Technology, VICI Properties and Safehold, cutting targets for Rollins and Alkami.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
8-K filing — ALKAMI TECHNOLOGY, INC. (ALKT)
Filed: 2026-10-07 AccNo: 0001529274-26-000056 Size: 142 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Alkami Stock Hits Three-Year Lows: Jana Doesn’t Get Buyout Wish
Alkami decided not to sell and shares plummeted on Thursday, hitting three-year lows and hurting Jana Partners' financial stake.
Craig-Hallum Maintains Buy on Compass Therapeutics, Lowers Price Target to $8
Craig-Hallum analyst Albert Lowe maintains Compass Therapeutics (NASDAQ:CMPX) with a Buy and lowers the price target from $15 to $8.
This Autoliv Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday
Analysts downgraded Accelerant, Autoliv, Compass Therapeutics, Wave Life Sciences and PG&E; price targets for CMPX and PCG were cut.
Citizens Maintains Market Outperform on Compass Therapeutics, Lowers Price Target to $4
Citizens analyst Reni J. Benjamin maintains Compass Therapeutics (NASDAQ:CMPX) with a Market Outperform and lowers the price target from $10 to $4.